Ireland - English - HPRA (Health Products Regulatory Authority)

sintetica uk limited - chloroprocaine hydrochloride - solution for injection - 10 milligram(s)/millilitre - esters of aminobenzoic acid; chloroprocaine

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sintetica ltd - bupivacaine hydrochloride; fentanyl citrate - solution for infusion - 1.25mg/1ml ; 2microgram/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sintetica ltd - fentanyl citrate; bupivacaine hydrochloride - solution for infusion - 2microgram/1ml ; 1.25mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sintetica ltd - bupivacaine hydrochloride; fentanyl - solution for infusion - 1mg/1ml ; 2microgram/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sintetica ltd - bupivacaine hydrochloride; fentanyl - solution for infusion - 1mg/1ml ; 2microgram/1ml

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

procaps, s.a. - dl-alfatocoferol acetato (vitamina e sintÉtica) equivalente a vitamina e - dl-alfatocoferol acetato (vitamina e sintÉtica) equivalente a vitamina e....400.00 ui

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

procaps s.a - dl-alfa tocoferil acetato/vitamina e sintetica - dl-alfa tocoferil acetato/vitamina e sintetica....400 ui

United States - English - NLM (National Library of Medicine)

sintetica us llc - bortezomib (unii: 69g8bd63pp) (bortezomib - unii:69g8bd63pp) - bortezomib for injection is indicated for the treatment of adult patients with multiple myeloma. bortezomib for injection is indicated for the treatment of adult patients with mantle cell lymphoma. bortezomib is contraindicated in patients with hypersensitivity (not including local reactions) to bortezomib, boron, or mannitol. reactions have included anaphylactic reactions [see adverse reactions ( 6.1)] . bortezomib is contraindicated for intrathecal administration. fatal events have occurred with intrathecal administration of bortezomib. risk summary based on its mechanism of action [see clinical pharmacology ( 12.1)] and findings in animals, bortezomib can cause fetal harm when administered to a pregnant woman. there are no studies with the use of bortezomib in pregnant women to inform drug-associated risks. bortezomib caused embryo-fetal lethality in rabbits at doses lower than the clinical dose (see data) . advise pregnant women of the potential risk to the fetus. adverse outc